Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AngioDynamics, Inc.
Israeli healthtech fund Accelmed is raising $100m for its fourth fund focused on medical device and digital health companies.
Medline Industries will pay $167.5m for the Namic brand of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. It also includes a manufacturing facility and the manufacturing, sales and marketing staff that support Namic.
The US Department of Justice collected $2.8bn in settlements and judgments involving violations of the False Claims Act in 2018, including $2.5bn in health-care cases. Key device industry recoveries included $33.2m from Alere, $12.5m from Angiodynamics, and $30m in two separate settlements from Covidien and its subsidiary ev3.
Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.
- Radiopharmaceuticals, Contrast Agents
- Consumables, Central Supplies
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
- Eximo Hybrid Medical Technologies
- Eximo Medical Ltd.
- Microsulis Medical Ltd.
- Navilyst Medical
- Vortex Meidcal, Inc.